PeerLINC trains San Lazaro Hospital teams in drug-resistant TB care

PeerLINC Knowledge Hub held a four-day training on drug-resistant tuberculosis (DR-TB) for medical staff at San Lazaro Hospital in Manila, Philippines, from October 26 to 29, 2026. Building on the country’s experience as an early adopter of the six-month BPaLM/BPaL regimens recommended by the World Health Organization (WHO), the training focused on selecting treatment regimens and on monitoring and managing adverse events.

The training paired a review of WHO guidelines with clinical exercises that asked participants to make decisions using the information available at different points in a patient’s care. Participants considered how drug resistance test results and coexisting health conditions could affect the choice of treatment, and what to look for once a person began a treatment regimen.

“We wanted to give physicians and nurses time to collaborate and work through the decisions they face in caring for people with drug-resistant TB,” said Dr. Eden Mendoza-Hisey, who introduced PeerLINC and presented the training overview. “Discussing a case, evaluating information, and asking questions allows the team to examine why a regimen may be appropriate for one person but not another.”

Choosing a treatment regimen

The first two days covered six-month DR-TB treatment options, including BPaL/M/C, as well as nine-month and longer regimens. Participants also reviewed treatment for isoniazid-resistant TB and discussed preventive treatment for people exposed to drug-resistant TB.

In a workshop led by Dr. Irene Flores of PeerLINC and Dr. Christian Villacorte, a member of PeerLINC’s Global Technical Expert Council (G-TEC), participants worked through six clinical cases. One scenario concerned a patient with rifampicin-resistant TB for whom further drug resistance testing was temporarily unavailable. Participants considered which regimen to start and whether it should be modified once results are available.

One participant recalled reviewing cases from their own practice during the sessions and reflecting on how they had approached care for those patients. “The training gave me more confidence in managing multidrug-resistant TB and helped me understand how to use shorter regimens with patients in my own practice,” said training participant Dr. Suyen Gutay. “At our facility, I expect it to help us accelerate adoption of patient management strategies in line with the latest guidance.”

Recognizing and managing adverse events

Dr. Flores introduced a framework for active TB drug safety monitoring and management. The session covered how teams assess symptoms and laboratory findings during treatment, respond to suspected adverse events, and document them for follow-up.

“A symptom that appears during treatment can have several possible causes,” said Dr. Flores. “Documenting what the patient was experiencing at the start of treatment helps the care team assess what has changed. It also gives them a clearer record to work from when they need to investigate or report an adverse event.”

Dr. Rholine Gem Veto of the Tropical Disease Foundation discussed how the Brief Peripheral Neuropathy Screening tool could be used before and during treatment. The video demonstration featured a patient who already had intermittent leg pain from a previous injury, illustrating how the care team could compare later symptoms with what the patient had reported before starting treatment. Other case discussions examined how to recognize and respond to adverse events involving vision, liver function, or heart rhythm.

Using diagnostic findings to guide care

The program also examined how diabetes, HIV, and chronic kidney disease can complicate TB care. In a separate laboratory diagnostics session, participants worked through scenarios that called for different tests. In one, they considered what further testing could uncover after an initial result detected rifampicin resistance. In another, they considered how to investigate suspected TB in a seriously ill patient with HIV who could not produce a sputum sample.

In the final evaluation, participants reflected on how they expected to use the training in their own facilities. Training participant Shirley Aguilar pointed to the role of their team in supporting patients as they undergo treatment. “The sessions helped me see how shorter regimens could make it easier for patients to stay on treatment,” she said. “I think it can make a difference in our TB-DOTS services because the skills of the team matter in how we support patients throughout their care.”

San Lazaro Hospital has a dedicated facility for drug-resistant TB care as part of its work as a national tertiary referral center for infectious and tropical diseases. Located in Santa Cruz, Manila, it is one of the Philippines’ oldest hospitals, tracing its origins to a dispensary established in 1577.

Next
Next

PeerLINC helps expand access to improved DR-TB treatments across Asia, new research shows